Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by BidaskClub

Alicia Farmer
January 13, 2018

(NASDAQ:SRPT) has been 1.75 million shares per day over the past 30 days. The institutional investor held 52,265 shares of the computer peripheral equipment company at the end of 2017Q3, valued at $1.10M, up from 31,500 at the end of the previous reported quarter. 2,309,800 shares of the company's stock were exchanged, compared to its average volume of 2,576,267. Legal & General Group Plc now owns 17,590 shares of the biotechnology company's stock worth $593,000 after acquiring an additional 663 shares during the last quarter.

UBS Group reiterated their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report sent to investors on Wednesday, December 27th, reports. It has outperformed by 80.12% the S&P500.

Shares of Sarepta Therapeutics (NASDAQ SRPT) traded up $2.99 during trading on Monday, hitting $59.14. To measure price-variation, we found SRPT's volatility during a week at 6.35% and during a month it has been found around 3.93%. The institutional investor held 27,047 shares of the technology company at the end of 2017Q3, valued at $4.62 million, up from 17,095 at the end of the previous reported quarter. Brouwer & Janachowski Llc bought 9,952 shares as the company's stock rose 10.88% with the market. The stock was bought at an average price of $52.44 per share, with a total value of $1,999,956.72. About 10.59M shares traded or 32.96% up from the average., inc. (NYSE:CRM) has risen 7.78% since January 10, 2017 and is uptrending. It has outperformed by 55.47% the S&P500.

Short interest or otherwise called the percentage of a stock's tradable shares now being shorted is another data that investors use to get a handle on sentiment. Its down 0.13, from 1.08 in 2017Q2. Through this figure traders can analyze that SRPT show whether or not a stock now most active and standing in buying side or sell side. 128 funds opened positions while 644 raised stakes. Columbus Circle Invsts reported 0.09% stake.

Sphera Funds Ltd accumulated 384,997 shares. Wetherby Asset Mngmt stated it has 12,126 shares or 0.17% of all its holdings. (NASDAQ:SRPT) that has shown a discernible change in trend levels over the path of recent market activity. Voya Investment Management Ltd Llc invested in 0.06% or 629,053 shares. Delta Asset Tn has 575 shares. Castleark Mgmt Lc holds 0.4% of its portfolio in Sarepta Therapeutics, Inc. On Tuesday, July 18 the stock rating was maintained by Leerink Swann with "Buy". (NASDAQ:SRPT). Schwab Charles Investment Mgmt Incorporated holds 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 952 shares. Great West Life Assurance Can accumulated 6,409 shares. Eam Invsts Limited Liability Corp has 61,155 shares for 0.37% of their portfolio. Natl Planning invested 0.05% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Driehaus Capital Ltd Llc accumulated 0.13% or 72,956 shares.

Critical Flaw Identified in Intel Processors
Google's cyber security researchers spotted a major flaw recently in the designing of Intel CPUs and users are not happy at all . However, at this time, AMD said its processors should have "near zero risk", reports Axios .

Alex Pritchard set for Huddersfield debut against West Ham
West Ham manager David Moyes wants his side to compete with the big teams in the Premier League . Speculation claims West Ham United are preparing a major striker clear-out.

Michael Owen comments on Riyad Mahrez to Liverpool speculation
Coutinho finally completed his long-awaited switch to Barcelona last weekend, ending a five year spell at Anfield in a deal worth £142m.

Since October 3, 2017, it had 0 buys, and 1 insider sale for $575,000 activity.

When we look at the Analyst Recommendations of the stock, the company has 1 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell. Therefore 24% are positive. The firm has "Buy" rating given on Wednesday, October 26 by Stifel Nicolaus. The company was maintained on Monday, October 10 by Wedbush. Moreover, D E Shaw has 0.01% invested in Sarepta Therapeutics, Inc. As per Wednesday, September 6, the company rating was maintained by J.P. Morgan. Credit Suisse has "Outperform" rating and $68 target. Goldman Sachs initiated Sarepta Therapeutics, Inc. KeyBanc Capital Markets has "Buy" rating and $11.0 target. SunTrust downgraded the shares of SRPT in report on Tuesday, April 26 to "Reduce" rating. As per Wednesday, March 23, the company rating was downgraded by JMP Securities. The rating was upgraded by Morgan Stanley on Monday, October 2 to "Overweight". Oppenheimer reaffirmed a "buy" rating on shares of Sarepta Therapeutics in a research note on Monday, September 25th. They expect $-0.35 EPS, up 77.85 % or $1.23 from last year's $-1.58 per share. AAPL's profit will be $19.08B for 11.63 P/E if the $3.75 EPS becomes a reality. After $-0.78 actual EPS reported by Sarepta Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -55.13 % EPS growth.

The stock received analysts' mean target price of $5.50. Therefore 67% are positive. On Thursday, September 7 the stock rating was maintained by Stifel Nicolaus with "Buy". (NASDAQ:AAPL), 40 have Buy rating, 1 Sell and 11 Hold. The firm has "Neutral" rating given on Wednesday, April 20 by Janney Capital. On Monday, December 14 the stock rating was upgraded by DA Davidson to "Buy". The firm has "Buy" rating given on Wednesday, August 5 by Roth Capital.

Investors sentiment increased to 0.7 in 2017 Q3. Its down 0.17, from 1.34 in 2017Q2. It fall, as 13 investors sold SBCF shares while 29 reduced holdings. 73 funds opened positions while 295 raised stakes. Boston Prtn stated it has 197,816 shares or 0.04% of all its holdings. Zacks' sales calculations are an average based on a survey of sell-side research analysts that follow Sarepta Therapeutics. Commercial Bank Of Nova Scotia holds 121,767 shares or 0.03% of its portfolio. Moreover, Hudson Valley Advsrs Adv has 0.89% invested in Celgene Corporation (NASDAQ:CELG). National Bank Of Ny Mellon reported 315,803 shares stake. Company insiders own 9.60% of the company's stock. Maltese Ltd Liability Company has invested 0.96% in Seacoast Banking Corporation of Florida (NASDAQ:SBCF). (NASDAQ:FB). Blair William And Il holds 1.19M shares. The debt ratio of VIAB is 1.84 compared to 0.04 for SRPT.

Other reports by

Discuss This Article